FDA Approves First New Sunscreen Ingredient in 27 Years, Promising Superior UVA Protection

For the first time in 27 years, Americans will soon have a fundamentally new way to protect their skin from the sun. On June 9, 2026, the U.S. Food and Drug Administration officially approved bemotrizinol—often referred to as BEMT—as a safe and effective active ingredient for over-the-counter sunscreens.

The landmark decision ends a decades-long regulatory freeze that had left U.S. consumers relying on older, often flawed chemical filters, even as more advanced options became standard across Europe and Asia. The approval marks a significant shift in public health policy, offering a highly effective tool to combat rising rates of melanoma and other skin cancers.[1][8]

Bemotrizinol represents a major technological leap over the chemical filters currently dominating U.S. pharmacy shelves. It is a broad-spectrum organic filter, meaning it effectively absorbs both ultraviolet A (UVA) rays, which drive premature aging and skin cancer, and ultraviolet B (UVB) rays, which cause sunburns. Crucially, bemotrizinol is highly photostable.

Older chemical ingredients like avobenzone degrade rapidly when exposed to sunlight, losing their protective power exactly when it is needed most unless stabilized by other chemicals. Bemotrizinol maintains its structural integrity under direct UV exposure, providing consistent, long-lasting protection without breaking down into potentially irritating byproducts.[2][5]

For many consumers, the most immediate benefit of the new filter will be cosmetic. While mineral sunscreens containing zinc oxide or titanium dioxide offer excellent, stable broad-spectrum protection, they are notorious for leaving a chalky white cast on the skin. This heavy residue often discourages daily use, particularly among people of color.

Bemotrizinol, by contrast, goes on completely clear. By offering the robust protection of a mineral block with the invisible, lightweight finish of a chemical lotion, dermatologists expect the new ingredient to significantly boost the daily sunscreen compliance required to meaningfully reduce skin cancer risks.[4][6]

The safety profile of bemotrizinol also addresses long-standing concerns about chemical sunscreens. In recent years, studies have shown that older chemical filters, such as oxybenzone, can absorb through the skin and enter the bloodstream at levels far exceeding the FDA's threshold of concern. Bemotrizinol was specifically engineered as a large molecule.

Because of its size, it cannot easily cross the skin barrier, meaning it remains on the surface where it belongs. Rigorous testing confirmed minimal systemic absorption, leading the FDA to clear the ingredient for use by adults and children as young as six months old.[5][7]

The approval closes what consumer advocates have long called the "UVA gap" in American sun care. Bemotrizinol is not a new invention; it was developed by Swiss chemists in the 1990s and has been used safely in Europe, Asia, and Australia since 1999 under brand names like Tinosorb S. For decades, American dermatologists have watched with frustration as international consumers enjoyed access to superior sun protection while U.S. formulations stagnated.

Advocacy groups like the Environmental Working Group have spent years petitioning the federal government to modernize its approved list, arguing that the lack of photostable UVA filters constituted a genuine public health vulnerability.[4][5]

The 27-year delay stems from how the United States categorizes sun protection. Unlike Europe, which regulates sunscreens as cosmetics, the FDA classifies them as over-the-counter drugs. This designation requires pharmaceutical-grade clinical trials to prove safety and efficacy—a massive financial hurdle for manufacturers.

The original application for bemotrizinol was filed in 2005 but languished in a regulatory backlog. The breakthrough finally came via the CARES Act of 2020, which modernized the FDA's over-the-counter monograph system and allowed regulators to consider real-world safety data from decades of international use, rather than relying solely on new domestic clinical trials.[4][8]

While the approval is official, Americans will have to wait a few more months to purchase products containing the new filter. The first sunscreens formulated with bemotrizinol are expected to reach U.S. store shelves in the fall of 2026. Under the current regulatory framework, DSM Nutritional Products—which manufactures the ingredient under the trade name Parsol Shield—holds an 18-month exclusivity window. During this period, they will be the sole supplier, though several major skincare brands have already announced agreements to incorporate the filter into their upcoming product lines.[3][6]

For readers evaluating their sun protection strategy this summer, the advice remains practical: do not wait for the new formulations to start protecting your skin. Existing sunscreens, particularly mineral options containing zinc oxide, still provide excellent defense when applied generously and reapplied every two hours. However, the impending arrival of bemotrizinol means that the most common barriers to daily sunscreen use—greasiness, white cast, and concerns about chemical absorption—are about to be definitively solved.[5][7]